SLS

NASDAQ 已收盘

SELLAS Life Sciences Group

14.86 USD
▼-3.09-17.21%
盘后 14.95 +0.59%
2026-11-19
市值
$2.78B
市盈率
—
EPS
-0.20
股息率
—
52 周区间
1.39 – 24.89
成交量
36.26M
Beta
2.71
目标价
37.50
52W 低 1.3952W 高 24.89
价格走势

公司简介

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli...